Patents by Inventor George Alexandrides

George Alexandrides has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6887897
    Abstract: Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: May 3, 2005
    Assignee: Mission Pharmacal Company
    Inventors: Neill B. Walsdorf, Sr., George Alexandrides
  • Patent number: 6818228
    Abstract: A vitamin and mineral supplement containing ULTRADENSE™ calcium citrate and carbonyl iron for use in humans. Calcium in the form of citrate enhances absorption of iron, zinc, and magnesium. ULTRADENSE™ calcium citrate provides more bioavailable calcium than usual preparations of calcium citrate. Carbonyl iron provides iron in a form that significantly reduces the risk to children of accidental iron poisoning from formulations that provide iron in salt form. The supplement may further contain a number of vitamins and minerals in a tablet that is elegantly small, weighing about 1.5-1.6 g. The small size allows ease of swallowing and encourages patient acceptability. Methods of making such a supplement and methods of treating maladies in need of vitamin and mineral supplementation are provided.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: November 16, 2004
    Assignee: Mission Pharmacal Company
    Inventors: Neill B. Walsdorf, Cindy L. Wabner, George Alexandrides
  • Publication number: 20030077331
    Abstract: Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
    Type: Application
    Filed: July 31, 2001
    Publication date: April 24, 2003
    Inventors: Neill B. Walsdorf, George Alexandrides
  • Patent number: 6287607
    Abstract: A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: September 11, 2001
    Assignees: Mission Pharmacal Company, Board of Regents, University of Texas System
    Inventors: Charles Y. C. Pak, George Alexandrides, Neill B. Walsdorf
  • Publication number: 20010003002
    Abstract: A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.
    Type: Application
    Filed: July 19, 1999
    Publication date: June 7, 2001
    Inventors: CHARLES Y. C. PAK, GEORGE ALEXANDRIDES, NEILL B. WALSDORF
  • Patent number: 5432200
    Abstract: A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.
    Type: Grant
    Filed: April 12, 1993
    Date of Patent: July 11, 1995
    Inventors: Neill B. Walsdorf, George Alexandrides, Charles Y. C. Pak
  • Patent number: 5219889
    Abstract: A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.
    Type: Grant
    Filed: December 3, 1991
    Date of Patent: June 15, 1993
    Assignees: The University of Texas System, Mission Pharmacal Company
    Inventors: Neill B. Walsdorf, George Alexandrides, Charles Y. C. Pak
  • Patent number: 5075499
    Abstract: One aspect of the present invention includes the novel compound having the formula:Ca.sub.2 (OOC--CH.sub.2 --COHCOO-CH.sub.2 COO)(CH.sub.3 CHOH-COO)In another aspect of the present invention, a method is provided for the treatment of a calcium related pathology. The inventive method includes the steps of providing a pharmaceutically acceptable composition, including as the active principle the compound dicalcium citrate-lactate, and administering to an individual in need thereof a therapeutically effective amount of said pharmaceutically acceptable composition.In yet another aspect of the present invention, a process is provided for producing the compound dicalcium citrate-lactate.
    Type: Grant
    Filed: November 21, 1988
    Date of Patent: December 24, 1991
    Assignees: Board of Regents, The University of Texas System, Mission Pharmacal Company
    Inventors: Neill B. Walsdorf, George Alexandrides, Charles Y. C. Pak
  • Patent number: 4985593
    Abstract: A dual mineral salt consisting essentially of magnesium, potassium and citrate. A method for manufacturing the subject salt in a form having a bulk density ranging from about 1.0 g/cc to about 1.3 g/cc is also disclosed, and the use of the subject salt as a dietary supplement are also disclosed.
    Type: Grant
    Filed: January 5, 1988
    Date of Patent: January 15, 1991
    Assignee: Mission Pharmacal Company, Inc.
    Inventors: Neill B. Walsdorf, George Alexandrides
  • Patent number: 4814177
    Abstract: A calcium citrate composition having a bulk density greater than about 1.1 g/cc. Citric acid and a calcium compound are mixed to produce a mixture having a calcium compound/citric acid molar ratio of about 1.5. A hydrated mixture percent is produced by agitatively adding water to the mixture, although when desired the calcium compound, citric acid and water mayBACKGROUND OF THE INVENTIONA portion of the development of the present invention was supported by Grant No. P01-AM 20543 from the United States Government, National Institutes of Health.
    Type: Grant
    Filed: August 13, 1986
    Date of Patent: March 21, 1989
    Assignees: Board of Regents, University of Texas System, Mission Pharmacal
    Inventors: Neill B. Walsdorf, George Alexandrides, Charles Y. C. Pak